 SEATTLE, WA VANCOUVER, BC ACCESSWIRE September 14, 2021 Achieve Life Sciences, Inc. NASDAQ:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine Tobacco SRNT-E Conference to be held virtually September 15-17, 2021. Presentation Details Cytisinicline may benefit smokers who previously failed to quit smoking with varenicline: A subgroup analysis of the ORCA-1 trial A subgroup analysis from the ORCA-1 Phase 2 study of smokers who had previously failed Chantix varenicline demonstrated a Week 4 abstinence rate of 51.3 upon treatment with cytisinicline using the three times daily TID regimen, compared with 15.8 with placebo p 0.009. 